Effects of Rifampin and Doxycycline Treatments in Patients With Uncomplicated Scrub Typhus: An Open-Label, Randomized, Controlled Trial

被引:16
作者
Kim, Yun Sung [1 ]
Kim, Dong-Min [1 ]
Yoon, Na-Ra [1 ]
Jang, Mi-Sun [1 ]
Kim, Choon-Mee [2 ]
机构
[1] Chosun Univ, Coll Med, Dept Internal Med, 588 Seosuk Dong, Gwangju 501717, South Korea
[2] Chosun Univ, Coll Med, Premed Sci, Gwangju, South Korea
关键词
scrub typhus; doxycycline; rifampin; Orientia tsutsugamushi; ORIENTIA-TSUTSUGAMUSHI; NORTHERN THAILAND; CLINICAL-PRACTICE; CHLORAMPHENICOL; AZITHROMYCIN; INFECTIONS; THERAPY; DISEASE;
D O I
10.1093/cid/ciy130
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Doxycycline is currently the most frequently used treatment in patients with scrub typhus. However, doxycycline-resistant strains have been found, necessitating the development of a new treatment. Rifampin is known to be effective even for such strains. Our aim in this study was to compare the effects of rifampin and doxycycline treatment in patients with scrub typhus in areas in which resistance to doxycycline has not been reported. Methods. Patients admitted to Chosun University Hospital and regional network hospitals between 2007 and 2009 with a body temperature >= 37.5 degrees C and suspected to have scrub typhus were randomly assigned to 1 of 2 treatment groups: a group administered doxycycline 100 mg twice daily for 5 days and a group administered rifampin 600 mg once daily for 5 days. For treatment outcomes, fever, headache, muscle ache, and rash clearance times were compared between the groups. Results. The rifampin and doxycycline groups showed equivalence in all treatment outcomes evaluated. The proportions of patients with fever clearance within 48 hours were similar between groups. Furthermore, there was no significant difference in the occurrence of side effects following drug administration between groups. Conclusions. On the basis of the finding that equivalent treatment effects and safety were found in patient groups that received 600 mg of rifampin and 200 mg of doxycycline, respectively, for 5 days to treat scrub typhus, rifampin may be considered an alternative treatment to doxycycline.
引用
收藏
页码:600 / 605
页数:6
相关论文
共 50 条
  • [21] Music Reduces Patient Anxiety During Mohs Surgery: An Open-Label Randomized Controlled Trial
    Vachiramon, Vasanop
    Sobanko, Joseph F.
    Rattanaumpawan, Pinyo
    Miller, Christopher J.
    DERMATOLOGIC SURGERY, 2013, 39 (02) : 298 - 305
  • [22] Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
    Meadowcroft, Amy M.
    Cizman, Borut
    Holdstock, Louis
    Biswas, Nandita
    Johnson, Brendan M.
    Joness, Delyth
    Nossuli, A. Kaldun
    Lepore, John J.
    Aarup, Michael
    Cobitz, Alexander R.
    CLINICAL KIDNEY JOURNAL, 2019, 12 (01) : 139 - 148
  • [23] Effect of tamsulosin on stone expulsion in proximal ureteral calculi: an open-label randomized controlled trial
    Lee, S. W.
    Woo, S. H.
    Yoo, D-S
    Park, J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (02) : 216 - 221
  • [24] Comparison of the effects of doxycycline and povidone iodine in treatment of pleural effusion; an open label randomized clinical trial
    Hemmati, Hamid Reza
    Hadjizadeh, Armin
    Malek, Farhad
    Ghorbani, Raheb
    Zahmatkesh, Mehrdad
    Soltani, Setareh
    IMMUNOPATHOLOGIA PERSA, 2024, 10 (02):
  • [25] Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial
    Grigg, Matthew J.
    William, Timothy
    Menon, Jayaram
    Dhanaraj, Prabakaran
    Barber, Bridget E.
    Wilkes, Christopher S.
    von Seidlein, Lorenz
    Rajahram, Giri S.
    Pasay, Cielo
    McCarthy, James S.
    Price, Ric N.
    Anstey, Nicholas M.
    Yeo, Tsin W.
    LANCET INFECTIOUS DISEASES, 2016, 16 (02) : 180 - 188
  • [26] Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial
    Arjyal, Amit
    Basnyat, Buddha
    Ho Thi Nhan
    Koirala, Samir
    Giri, Abhishek
    Joshi, Niva
    Shakya, Mila
    Pathak, Kamal Raj
    Mahat, Saruna Pathak
    Prajapati, Shanti Pradhan
    Adhikari, Nabin
    Thapa, Rajkumar
    Laura Merson
    Gajurel, Damodar
    Lamsal, Kamal
    Lamsal, Dinesh
    Yadav, Bharat Kumar
    Shah, Ganesh
    Shrestha, Poojan
    Dongol, Sabina
    Karkey, Abhilasha
    Corinne N Thompson
    Nga Tran Vu Thieu
    Duy Pham Thanh
    Baker, Stephen
    Guy E Thwaites
    Marcel Wolbers
    Christiane Dolecek
    LANCET INFECTIOUS DISEASES, 2016, 16 (05) : 535 - 545
  • [27] Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial
    Xu, Lingling
    Liu, Shiqun
    Guan, Meiping
    Xue, Yaoming
    MEDICAL SCIENCE MONITOR, 2016, 22 : 810 - 817
  • [28] Effect of Pranayama as Adjuvant to Medical Treatment on Severity, Frequency, and Duration of Headache in Migraine Patients: An Open-Label Randomized Controlled Trial
    Kaushal, Anjana
    Padam, Anita
    Sharma, Minoo
    Sharma, Sudhir
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2023, 26 (05) : 690 - +
  • [29] Autoinoculation versus 35% trichloroacetic acid for the treatment of molluscum contagiosum: An open-label randomized controlled trial
    Saraswat, Shweta
    Choudhary, Paras
    Joshi, Yogi R.
    Yadav, Chinmai
    Kachhawa, Dilip
    Choudhary, Durga
    Singh, Harshvardhan
    TURK DERMATOLOJI DERGISI-TURKISH JOURNAL OF DERMATOLOGY, 2022, 16 (01): : 16 - 22
  • [30] Perioperative Fully Closed-Loop Insulin Delivery in Patients Undergoing Elective Surgery: An Open-Label, Randomized Controlled Trial
    Herzig, David
    Suhner, Simon
    Roos, Jonathan
    Schurch, Daniel
    Cecchini, Luca
    Nakas, Christos T.
    Weiss, Salome
    Kadner, Alexander
    Kocher, Gregor J.
    Guensch, Dominik P.
    Wilinska, Malgorzata E.
    Raabe, Andreas
    Siebenrock, Klaus A.
    Beldi, Guido
    Gloor, Beat
    Hovorka, Roman
    Vogt, Andreas P.
    Bally, Lia
    DIABETES CARE, 2022, 45 (09) : 2076 - 2083